Markets:

Overview

News

Currencies

International

Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

332.29 -0.13 (-0.04%)

Streaming Delayed Price Updated: 12:23 PM EDT, Apr 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance

April 15, 2026

As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9...

Via MarketMinute

Topics Economy

Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A

April 15, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately...

Via MarketMinute

Topics Economy

Penumbra Inc (NYSE:PEN) Combines Strong Growth with Bullish Chart Setup ↗

March 19, 2026

Via Chartmill

Penumbra Inc (NYSE:PEN) Combines Strong Fundamentals with Bullish Technical Setup ↗

February 24, 2026

Via Chartmill

Wall Street’s Renaissance: Bank of America Shatters Q1 2026 Estimates as M&A and Trading Volatility Surge

April 15, 2026

The financial landscape of 2026 has been marked by a return to high-stakes deal-making and intense market fluctuations, and no institution seems more equipped to navigate this era than Bank of America...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Avanos Medical to be Acquired by American Industrial Partners for $1.27 Billion; Stock Surges 69%

April 14, 2026

The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American...

Via MarketMinute

Topics Economy

1 Mid-Cap Stock on Our Buy List and 2 We Ignore

April 13, 2026

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Via StockStory

Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & Supplies - Cardiology, Neurology, Vascular Group

April 06, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Penu...

Via StockStory

1 Profitable Stock on Our Buy List and 2 We Brush Off

April 03, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

The Great Unlocking: 2026 M&A Surge Ignites as Private Equity Confidence Hits Record 86%

April 02, 2026

NEW YORK — The global mergers and acquisitions (M&A) market has entered a period of unprecedented expansion in the first half of 2026, marking a definitive end to the "deal desert" of previous years....

Via MarketMinute

Topics Artificial Intelligence Economy Government

Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability

April 02, 2026

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided...

Via MarketMinute

Topics Economy Retirement

2 Reasons to Avoid PEN and 1 Stock to Buy Instead

March 30, 2026

While the broader market has struggled with the S&P 500 down 3.2% since September 2025, Penumbra has surged ahead as its stock price has climbed by 32.3% to ...

Via StockStory

Topics Stocks Supply Chain

The $1 Trillion Resurrection: Global M&A Hits Historic Milestone in Q1 2026 as Jefferies Eyes 'Strategic Renaissance'

March 27, 2026

The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity ↗

March 24, 2026

Via MarketBeat

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

1 Growth Stock to Stash and 2 We Avoid

March 12, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

The $2.5 Trillion Tsunami: Why 2026 has Become the Year of the Megadeal

March 10, 2026

As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise....

Via MarketMinute

Topics Artificial Intelligence Economy Government

The 2026 M&A Resurgence: Private Equity Confidence Hits Record Highs

March 09, 2026

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

3 Cash-Heavy Stocks That Fall Short

March 09, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

3 Cash-Producing Stocks We Approach with Caution

March 05, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025

February 25, 2026

Medical device company Penumbra (NYSE:PEN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 22.1% year on year to $385.4 million. Its non-GAAP profit of $1.18 per share was 6.1%...

Via StockStory

Medtronic Hits 10-Quarter High: PFA Dominance and Robotic Surges Signal a New Era for MedTech

February 23, 2026

In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape

February 19, 2026

On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire...

Via MarketMinute

1 Profitable Stock with Impressive Fundamentals and 2 We Brush Off

February 11, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

The $3.2 Trillion ‘Wall of Capital’: Private Equity Unleashes a Global M&A Renaissance in 2026

February 06, 2026

As of February 6, 2026, the global financial landscape is being reshaped by an unprecedented "wall of capital." After nearly two years of stagnation caused by valuation gaps and high borrowing costs,...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

The Great Rebound: US M&A Activity Surges 111% as Megadeals Return to Wall Street

February 06, 2026

The long-awaited "deal drought" has officially broken. As of early February 2026, the American financial landscape is being reshaped by a massive resurgence in corporate deal-making, punctuated by a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition

February 05, 2026

In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for...

Via MarketMinute

Topics Supply Chain

The Return of the Giants: Private Equity Mega-Deals Surge in Early 2026

February 05, 2026

The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

Why Boston Scientific Stock Plummeted Today ↗

February 04, 2026

I'll be keeping a close eye on Boston Scientific stock following the market's peculiar reaction to its solid earnings report.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.